MedPath

Hydroxychloroquine sulfate

These highlights do not include all the information needed to use HYDROXYCHLOROQUINE SULFATE TABLETS safely and effectively. See full prescribing information for HYDROXYCHLOROQUINE SULFATE TABLETS. HYDROXYCHLOROQUIN SULFATE tablets, for oral use Initial U.S. Approval: 1955

Approved
Approval ID

6a06ad3d-2d6c-4e51-93f5-8f782b86975b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 31, 2023

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Hydroxychloroquine sulfate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50090-5573
Application NumberANDA040657
Product Classification
M
Marketing Category
C73584
G
Generic Name
Hydroxychloroquine sulfate
Product Specifications
Route of AdministrationORAL
Effective DateAugust 26, 2023
FDA Product Classification

INGREDIENTS (8)

MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
DIBASIC CALCIUM PHOSPHATE DIHYDRATEInactive
Code: O7TSZ97GEP
Classification: IACT
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
TALCInactive
Code: 7SEV7J4R1U
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
HYDROXYCHLOROQUINE SULFATEActive
Quantity: 200 mg in 1 1
Code: 8Q2869CNVH
Classification: ACTIB
POLYVINYL ALCOHOL, UNSPECIFIEDInactive
Code: 532B59J990
Classification: IACT

Drug Labeling Information

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 8/26/2023

6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections:

  • Cardiomyopathy and Ventricular Arrhythmias [see Warnings and Precautions (5.1)]
  • Retinal Toxicity [see Warnings and Precautions (5.2)]
  • Serious Skin Reactions [see Warnings and Precautions (5.3)]
  • Worsening of Psoriasis [see Warnings and Precautions (5.4)]
  • Risks Associated with Use in Porphyria [see Warnings and Precautions (5.5)]
  • Hematologic Toxicity [see Warnings and Precautions (5.6)]
  • Hemolytic Anemia Associated with G6PD [see Warnings and Precautions (5.7)]
  • Skeletal Muscle Myopathy or Neuropathy [see Warnings and Precautions (5.8)]
  • Neuropsychiatric Reactions Including Suicidality [see Warnings and Precautions (5.9)]
  • Hypoglycemia [see Warnings and Precautions (5.10)]

The following adverse reactions have been identified during post-approval use of 4 -aminoquinoline drugs, including hydroxychloroquine sulfate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:

  • Blood and lymphatic system disorders: Bone marrow depression, anemia, aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia
  • Cardiac disorders: Cardiomyopathy, cardiac failure, QT-interval prolongation, ventricular tachycardia, torsades de pointes, atrioventricular block, bundle branch block, sick sinus syndrome, pulmonary hypertension
  • Ear and labyrinthdisorders: Vertigo, tinnitus, nystagmus, sensorineural hearing loss
  • Eye disorders: Retinopathy, retinal pigmentation changes (typically bull's eye appearance), visual field defects (paracentral scotomas), macular degeneration, corneal edema, corneal opacities, decreased dark adaptation
  • Gastrointestinal disorders: Nausea, vomiting, diarrhea, abdominal pain
  • General disorders: Fatigue
  • Hepatobiliary disorders: Abnormal liver function tests, fulminant hepatic failure
  • Immune system disorders: Urticaria, angioedema, bronchospasm
  • Metabolism and nutrition disorders: Anorexia, hypoglycemia, weight loss
  • Musculoskeletal and connective tissue disorders: Proximal myopathy, depressed tendon reflexes, abnormal nerve conduction
  • Nervous system disorders: Ataxia, dizziness, headache, seizure, extrapyramidal disorders (dystonia, dyskinesia, tremor)
  • Neuropsychiatric disorders: Affect/emotional lability, irritability, nervousness, psychosis, suicidal ideation, suicidal behavior, depression, hallucinations, anxiety, agitation, confusion, delusions, paranoia, mania and sleep disorders (insomnia, night terrors, nightmares)
  • Skin and subcutaneous tissue disorders: Alopecia, hair color changes, rash, pruritus, photosensitivity, psoriasis exacerbation, hyperpigmentation, exfoliative dermatitis, erythema multiforme, acute generalized exanthematous pustulosis, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS syndrome), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)
Key Highlight

The most common adverse reactions reported are: nausea, vomiting, diarrhea, and abdominal pain. (6)

To report SUSPECTED ADVERSE REACTIONS, contact****Northstar Rx LLC at 1-800-206-7821 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 8/25/2023

Manufactured for:

Northstar Rx LLC

Memphis, TN 38141.

Manufactured by:

Zydus Lifesciences Ltd.

Ahmedabad, India.

Rev.: 08/23

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Hydroxychloroquine sulfate - FDA Drug Approval Details